Leveraging cutting-edge technology to address the impact of COVID-19 on cancer screening, diagnosis, and treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Omicron variant of SARS-CoV-2 is a powerful reminder that the COVID-19 pandemic, now entering its third year, will continue to have personal and public health impacts. This may be especially true for those individuals who unfortunately missed or delayed cancer screening or treatment as a result of the pandemic. 

More than ever, effective and widespread use of cutting-edge cancer therapies will be essential for addressing the challenges arising from these delays and helping those diagnosed with cancer achieve optimal outcomes.

The American Cancer Society estimates that 22 million cancer screenings were missed or canceled between March and June 2020 in the United States alone, resulting in a 46% decrease in the diagnosis of six different cancers included the study. 

Another study, conducted at Massachusetts General Hospital and Harvard Medical School, found that CT-based cancer screenings fell 82% during the first COVID-19 peak in spring 2020 compared with pre-pandemic levels.1 Similarly, a Canadian study found that there was a 41% decrease in screening tests administered in 2020 compared with 2019.2 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Gustaf Salford
President and CEO, Elekta
Table of Contents

YOU MAY BE INTERESTED IN

Arineta, a provider of cardiovascular imaging solutions, announced that its SpotLight Duo cardiac CT scanner has received 510(k) clearance from FDA for low-dose lung cancer screening. This clearance allows providers to use a single ultra-fast CT platform for both cardiac and lung imaging and diagnostics, delivering more complete care to high-risk patients.
According to a recent report, “The Cancer Paradox: Oncologists’ Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring,” oncologists believe they are seeing more and more patients with advanced cancers, and that screening barriers are the leading reason why. They worry that current tests may not catch cancer recurrence early enough.
Gustaf Salford
President and CEO, Elekta

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login